Shijiazhuang Yiling Pharmaceutical Co., Ltd. (SHE:002603)
China · Delayed Price · Currency is CNY 17.43
+0.13 (0.75%)
Feb 3, 2026, 9:55 AM CST
SHE:002603 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Operating Revenue | 6,008 | 6,506 | 10,315 | 12,520 | 10,111 | 8,774 |
Other Revenue | 6.99 | 6.99 | 3.48 | 13.04 | 6.12 | 8.42 |
| 6,015 | 6,513 | 10,318 | 12,533 | 10,117 | 8,782 | |
Revenue Growth (YoY) | -25.82% | -36.88% | -17.67% | 23.88% | 15.19% | 50.77% |
Cost of Revenue | 2,835 | 3,486 | 4,434 | 4,556 | 3,700 | 3,125 |
Gross Profit | 3,180 | 3,027 | 5,884 | 7,976 | 6,417 | 5,658 |
Selling, General & Admin | 2,619 | 2,935 | 3,297 | 3,871 | 3,931 | 3,436 |
Research & Development | 798.67 | 826.57 | 853.19 | 1,032 | 792.16 | 654.39 |
Other Operating Expenses | 140.33 | 91.72 | 99.27 | 203.45 | 138.41 | 136.29 |
Operating Expenses | 3,546 | 3,864 | 4,271 | 5,123 | 4,898 | 4,231 |
Operating Income | -366.08 | -837.02 | 1,613 | 2,853 | 1,519 | 1,426 |
Interest Expense | -1.3 | -29.01 | -38.9 | -33.8 | -33.97 | -10.96 |
Interest & Investment Income | 46.96 | 47.81 | 42.04 | 12.9 | 20.45 | 38.51 |
Currency Exchange Gain (Loss) | 1.46 | 1.46 | -0.21 | 4.16 | -1.25 | 0.02 |
Other Non Operating Income (Expenses) | 28.52 | -2.62 | -4.83 | -49.4 | -3.31 | -16.57 |
EBT Excluding Unusual Items | -290.44 | -819.39 | 1,611 | 2,787 | 1,501 | 1,437 |
Impairment of Goodwill | -6.24 | -6.24 | -0.52 | - | - | - |
Gain (Loss) on Sale of Investments | -38.98 | - | 39.35 | 11.5 | -21.9 | 5.23 |
Gain (Loss) on Sale of Assets | 0.92 | -0.49 | -0.82 | -3.11 | -3.37 | 0.14 |
Asset Writedown | -33.83 | -0.77 | -10.63 | -95.62 | -9.91 | -53.12 |
Other Unusual Items | 65.9 | 26.68 | 45.88 | 80.56 | 88.23 | 32.87 |
Pretax Income | -302.66 | -800.19 | 1,684 | 2,781 | 1,554 | 1,422 |
Income Tax Expense | -16.07 | -66.01 | 339.91 | 422.87 | 212.09 | 207.54 |
Earnings From Continuing Operations | -286.6 | -734.18 | 1,344 | 2,358 | 1,342 | 1,215 |
Minority Interest in Earnings | 7.71 | 9.67 | 8.08 | 4.98 | 2.22 | 3.81 |
Net Income | -278.89 | -724.52 | 1,352 | 2,363 | 1,344 | 1,219 |
Net Income to Common | -278.89 | -724.52 | 1,352 | 2,363 | 1,344 | 1,219 |
Net Income Growth | - | - | -42.76% | 75.82% | 10.27% | 100.95% |
Shares Outstanding (Basic) | 1,671 | 1,671 | 1,671 | 1,671 | 1,671 | 1,671 |
Shares Outstanding (Diluted) | 1,671 | 1,671 | 1,671 | 1,671 | 1,671 | 1,671 |
Shares Change (YoY) | 0.01% | -0.01% | -0.01% | 0.01% | -0.00% | 0.35% |
EPS (Basic) | -0.17 | -0.43 | 0.81 | 1.41 | 0.80 | 0.73 |
EPS (Diluted) | -0.17 | -0.43 | 0.81 | 1.41 | 0.80 | 0.73 |
EPS Growth | - | - | -42.76% | 75.81% | 10.27% | 100.25% |
Free Cash Flow | 1,338 | 320.62 | -155.38 | 3,274 | -144.87 | 441.39 |
Free Cash Flow Per Share | 0.80 | 0.19 | -0.09 | 1.96 | -0.09 | 0.26 |
Dividend Per Share | 0.300 | - | 0.300 | 0.500 | 0.300 | 0.714 |
Dividend Growth | - | - | -40.00% | 66.67% | -58.00% | 399.86% |
Gross Margin | 52.86% | 46.47% | 57.03% | 63.64% | 63.43% | 64.42% |
Operating Margin | -6.09% | -12.85% | 15.63% | 22.77% | 15.01% | 16.24% |
Profit Margin | -4.64% | -11.13% | 13.11% | 18.85% | 13.28% | 13.88% |
Free Cash Flow Margin | 22.25% | 4.92% | -1.51% | 26.12% | -1.43% | 5.03% |
EBITDA | 279.39 | -236.48 | 2,153 | 3,294 | 1,871 | 1,695 |
EBITDA Margin | 4.64% | -3.63% | 20.87% | 26.28% | 18.50% | 19.29% |
D&A For EBITDA | 645.47 | 600.54 | 540.64 | 440.6 | 352.61 | 268.16 |
EBIT | -366.08 | -837.02 | 1,613 | 2,853 | 1,519 | 1,426 |
EBIT Margin | -6.09% | -12.85% | 15.63% | 22.77% | 15.01% | 16.24% |
Effective Tax Rate | - | - | 20.18% | 15.21% | 13.65% | 14.59% |
Revenue as Reported | 6,015 | 6,513 | 10,318 | 12,533 | 10,117 | 8,782 |
Advertising Expenses | - | 169.83 | 257.93 | - | - | - |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.